Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +40.59%
#2 Bitway Bitway +24.85%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.60%
#4 Starpower Starpower +20.76%
#5 aelf aelf +18.07%
#6 Pons Pons +15.54%
#7 Decred Decred +13.45%
#8 Venom Venom +12.68%
#9 DAPPOS DAPPOS +11.63%
#10 Ribbita by Virtuals Ribbita by Virtuals +11.17%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

OTLC
Clasificación en acciones #30395
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Precio por acción
$0.03834
Última sincronización: 2026-08-18
Capitalización bursátil
$17.01M
Cambio (1 día)
-4.15%
Cambio (1 año)
-24.82%
País
US
Comercio Oncotelic Therapeutics, Inc. (OTLC)

Categoría

Healthcare
Ganancias de Oncotelic Therapeutics, Inc. (OTLC)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Oncotelic Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Oncotelic Therapeutics, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE